A Non-pharmacological Cough Control Therapy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04767074 |
|
Recruitment Status :
Recruiting
First Posted : February 23, 2021
Last Update Posted : July 13, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cough ILD Pulmonary Disease Pulmonary Fibrosis | Other: Non-pharmacological Cough control Therapy | Not Applicable |
Research questions and hypotheses
i) Is a non-pharmacological cough control therapy feasible to treat chronic cough in patients with ILD? Hypothesis: Given the results of previous non-pharmacological interventions in patients with refractory cough, we predict that this intervention will be feasible and well accepted in patients with ILD.
ii) Is a non-pharmacological cough control therapy more effective than pulmonary rehabilitation (PR) alone to treat chronic cough in patients with ILD? Hypotheses: Given the results of previous non-pharmacological interventions in patients with refractory cough, we predict that improvements observed in participants receiving the non-pharmacological intervention will exceed those receiving PR alone. Improvements are expected in HRQOL (exceeding the minimal clinically important difference), intensity of cough-related sensations and symptoms of fatigue.
Research Design The proposed research is a feasibility pre-post intervention study.
Study details:
Adults with ILD and chronic cough will be enrolled in this study. Potential eligible patients will be recruited from the outpatient PR program at West Park Healthcare Centre and St. Joseph's Healthcare. As the outpatient pulmonary rehabilitation program at West Park Healthcare Center and St. Joseph's Healthcare will transition partially to virtual meetings, the interactions between the research team and patients will be completed via phone calls or online.
This research study will be delivered online using the Zoom Healthcare Plan, an online platform that is available at West Park Healthcare Centre, and is used for telerehabilitation programs. Participants will be enrolled into a PR program composed of aerobic and strengthening exercises, disease-specific education and self-management, as part of their usual care. Two weeks before termination of PR, participants will start the non-pharmacological cough control therapy, following the intervention proposed by Chamberlain colleagues (2017). Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management
This study will measure several clinical outcomes.
- Feasibility will be reflected by the number of eligible patients enrolling (enrolment rate of at least 75%) and completing the intervention (attendance rate of at least 80%), compliance with the sessions and adverse events.
- Leicester cough questionnaire
- The King's Brief Interstitial Lung Disease (KBILD)
- Modified Borg scale (mBorg
- Cough Hypersensitivity Questionnaire (CHQ)
- Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F)
- Global rating of change questionnaire (GRCQ)
- Satisfaction Semi-structured interviews using open-ended questions will be conducted before and after the cough control intervention to capture participants' expectations and perspectives about the cough control therapy.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 24 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | Feasibility Pre/Post interventional study |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Non-pharmacological Cough Control Therapy as an Adjuvant of Pulmonary Rehabilitation in People With Interstitial Lung Diseases and Chronic Cough - A Feasibility Study |
| Actual Study Start Date : | September 1, 2020 |
| Estimated Primary Completion Date : | December 2022 |
| Estimated Study Completion Date : | December 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Non-pharmacological Cough control therapy
Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management. Sessions will be designed to target participants' needs and expectations according to the semi-structured theme. Session 1 General assessment Prescription of cough technique Session 2 Cough principles of cough Cough control Session 3 Breathing pattern retraining and laryngeal hygiene Session 4 Reinforcement of cough control therapies |
Other: Non-pharmacological Cough control Therapy
Participants will attend four virtual sessions of 45 to 60 minutes of educational and self-management. Session 1 General assessment Prescription and taught of one cough suppression technique. Session 2 Cough principles: mechanism, cough reflex, chronic cough, the importance of cough and negative effects of repeated coughing. Cough control: identify triggers, use cough suppressions and distractions techniques. Session 3 Breathing pattern retraining and laryngeal hygiene: reinforce nasal breathing and pursed lips breathing as strategies to avoid the urge to cough, identification of risk factors for laryngeal dehydration and hydration education. Session 4 Reinforcement: Clarification of doubts, techniques' reinforcement and application during daily life situations. Other Name: Cough Control therapy |
- Feasibility of intervention [ Time Frame: through study completion, average 1 year ]intervention feasibility will be reflected by the number of eligible patients enrolling (enrolment rate of at least 75%) and completing the intervention (attendance rate of at least 80%), compliance with the sessions and adverse events.
- Leicester cough questionnaire [ Time Frame: through study completion, average 1 year ]The LCQ is a validated 19-item cough-specific HRQoL questionnaire. It is divided into 3 domains (physical, social and psychological) and the overall score range from 3 to 21, with a higher score indicating a better cough related HRQOL.
- The King's Brief Interstitial Lung Disease (KBILD) [ Time Frame: through study completion, average 1 year ]The KBILD is a self-completed health status questionnaire that comprises of 15 items with the following three domains: psychological, breathlessness and activities and chest symptoms. Total score ranges from 0 to 100; 100 representing the best health status. This KBILD has an established minimal clinically important difference of 5-points in people with ILD.
- Modified Borg scale (mBorg) [ Time Frame: through study completion, average 1 year ]The modified Borg scale is widely used to assess the intensity of dyspnoea in individuals with chronic respiratory diseases and has recently been successfully adopted to assess the urge to cough and severity of cough in this population. The mBorg is measured on a 10 point scale; with 0 as feelings of "nothing at all" (no signs of dyspnoea) to 10 as "very very hard" intensity of dyspnoea.
- Cough Hypersensitivity Questionnaire (CHQ) [ Time Frame: through study completion, average 1 year ]The presence of triggers and laryngeal symptoms associated with cough were recorded using a standardized novel questionnaire, the CHQ. The CHQ comprises 23 items related to cough triggers, urge and laryngeal sensations associated with cough.
- Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-F) [ Time Frame: through study completion, average 1 year ]The FACIT-F is, a multi-dimensional 13-item questionnaire assessing tiredness, weakness and difficulty in handling daily living activities due to fatigue, over the previous 7 days. Participants are asked to rate their level of fatigue on a 4-point scale, where 0-not very much to 4- very much so. The sum of these values will provide a FACIT-F score ranging 0 to 52 (less fatigue to most fatigue).
- Global rating of change questionnaire (GRCQ) [ Time Frame: through study completion, average 1 year ]The GRCQ is a 15-point scale widely used to determine the participants' and health. professionals' perceptions about cough changes after interventions. Participants will be asked to rate global changes in cough in a scale ranging from -7 (a great deal worse) to +7 (a great deal better).
- Satisfaction of cough therapy program [ Time Frame: through study completion, average 1 year ]Participants' satisfaction and perceived benefits will be evaluated following completion of the intervention participants with a 9-item survey previously used to assess interventions in chronic respiratory diseases. The survey asks participants to report their level of agreement with statements on enjoyment and perceived improvements/benefits according to a 5-point Likert type scale (1=strongly agree; 5=strongly disagree).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Individuals will be included if having confirmed diagnosis of any ILD by a physician (as per Canadian Thoracic Society's guideline for evaluating patients with fibrotic interstitial lung disease) and a chronic cough lasting more than 8 weeks in duration
Exclusion Criteria:
- self-reports of moderate or large sputum production
- effective or suspected exacerbation of the respiratory condition in the past month
- upper respiratory tract infection in the past month
- use of angiotensin-converting enzyme inhibitor medication
- changes in the prescribed medication in the previous month
- evidence of traction bronchiectasis in the HRCT
- evidence of other medical conditions that prevent performance of an exercise training program
- unable to read or speak in English / unable to provide informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04767074
| Contact: Ana Oliveira, PhD | 6477651525 | ana.oliveira@westpark.org |
| Canada, Ontario | |
| St. Joseph's Healthcare Hamilton | Recruiting |
| Hamilton, Ontario, Canada | |
| Contact: Ana Oliveira, PhD ana.oliveira@westpark.org | |
| Contact: Dina Brooks, PhD 4165058953 brookd8@mcmaster.ca | |
| West Park Healthcare Centre | Recruiting |
| Toronto, Ontario, Canada, M6M 2J5 | |
| Contact: Ana Oliveria, PhD 6477651525 ana.oliveira@westpark.org | |
| Contact: Shirley Quach Shirley.Quach@westpark.org | |
| Sub-Investigator: Dina Brooks, PhD | |
| Sub-Investigator: Roger Goldstein, MD | |
Publications:
| Responsible Party: | Dina Brooks, Senior Scientist, West Park Healthcare Centre |
| ClinicalTrials.gov Identifier: | NCT04767074 |
| Other Study ID Numbers: |
20-005-WP |
| First Posted: | February 23, 2021 Key Record Dates |
| Last Update Posted: | July 13, 2022 |
| Last Verified: | July 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Cough ILD Pulmonary rehabilitation chronic cough non-pharmacological cough therapy |
|
Pulmonary Fibrosis Cough Lung Diseases Respiratory Tract Diseases Respiration Disorders Signs and Symptoms, Respiratory Phenylpropanolamine Guaifenesin Chlorpheniramine, phenylpropanolamine drug combination Expectorants Respiratory System Agents Adrenergic alpha-Agonists |
Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Appetite Depressants Anti-Obesity Agents Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Nasal Decongestants Vasoconstrictor Agents |